NASDAQ:IVA

Inventiva (IVA) Stock Forecast, Price & News

$4.26

+0.10 (+2.40%)

(As of 05:19 PM ET)

Compare

Today's Range: $4.00
▼
$4.30
50-Day Range: $3.41
▼
$4.44
52-Week Range: $2.22
▼
$11.75

Volume: 3,023 shs
Average Volume: 62,032 shs
Market Capitalization: $220.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.33

Inventiva MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 372.7% Upside
$19.33 Price Target
Short Interest: Healthy
0.18% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.20
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.95) to ($1.98) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

457th out of 975 stocks

Pharmaceutical Preparations Industry

203rd out of 456 stocks

3.5

Analyst's Opinion

Consensus Rating
Inventiva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.33, Inventiva has a forecasted upside of 372.7% from its current price of $4.09.
Amount of Analyst Coverage
Inventiva has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.18% of the outstanding shares of Inventiva have been sold short.
Short Interest Ratio / Days to Cover
Inventiva has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Inventiva has recently decreased by 5.61%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Inventiva does not currently pay a dividend.
Dividend Growth
Inventiva does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IVA.

2.3

News and Social Media Coverage

News Sentiment
Inventiva has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Inventiva this week, compared to 2 articles on an average week.
MarketBeat Follows
1 people have added Inventiva to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inventiva insiders have not sold or bought any company stock.
Percentage Held by Insiders
32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.46% of the stock of Inventiva is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Inventiva are expected to decrease in the coming year, from ($1.95) to ($1.98) per share.
Price to Book Value per Share Ratio
Inventiva has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Inventiva (NASDAQ:IVA) Stock

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

IVA Price History

30 days | 90 days | 365 days | Advanced Chart

IVA Stock News Headlines

September 26, 2023 | americanbankingnews.com

Inventiva (IVA) to Release Earnings on Thursday

September 23, 2023 | americanbankingnews.com

Inventiva's (IVA) "Buy" Rating Reaffirmed at Roth Mkm

September 28, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 21, 2023 | markets.businessinsider.com

Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease

September 21, 2023 | markets.businessinsider.com

Pre-market Movers: MURF, IFRX, NEPT, UPTD, AEHL…

September 20, 2023 | marketwatch.com

Inventiva ADRs Rise 9% Following Licensing Deal

September 20, 2023 | finance.yahoo.com

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

September 20, 2023 | finance.yahoo.com

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

September 28, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 20, 2023 | americanbankingnews.com

Critical Comparison: Nurix Therapeutics (NASDAQ:NRIX) and Inventiva (NASDAQ:IVA)

September 12, 2023 | msn.com

Industry slow to embrace new fatty liver disease nomenclature

August 31, 2023 | msn.com

urban-gro announces sale of investment for proceeds of $2.3 million

August 31, 2023 | msn.com

Inventiva announced €35.7M funding, eyes future raise to meet obligations

August 31, 2023 | finance.yahoo.com

Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates

August 14, 2023 | msn.com

Drugmakers still chasing potentially lucrative NASH market, despite setbacks

July 28, 2023 | finanznachrichten.de

INVENTIVA: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

July 28, 2023 | finance.yahoo.com

Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

July 28, 2023 | finance.yahoo.com

Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

July 28, 2023 | finance.yahoo.com

Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

June 24, 2023 | finance.yahoo.com

Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

June 16, 2023 | benzinga.com

HC Wainwright & Co. Reiterates Buy on Inventiva, Maintains $35 Price Target

June 16, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Inventiva (IVA)

June 16, 2023 | markets.businessinsider.com

Where Inventiva Stands With Analysts

June 14, 2023 | msn.com

Inventiva jumps 25% after mid-stage data for NASH candidate

June 14, 2023 | markets.businessinsider.com

Inventiva Rises In Morning Trade

June 14, 2023 | msn.com

Inventiva Soars on Promising Phase 2 Data in Fatty Liver Disease

June 14, 2023 | finance.yahoo.com

Inventiva's Lanifibranor Significantly Reduces NAFLD and Improves Type 2 Diabetes Control, Phase 2 Study Shows

See More Headlines

Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

IVA Company Calendar

Today: 9/28/2023
Next Earnings (Confirmed): 9/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IVA
CUSIP: N/A
CIK: 1756594
Web: www.inventivapharma.com
Phone: 33-3-80-44-75-00
Fax: N/A
Employees: 109
Year Founded: 2011

Price Target and Rating

Average Stock Price Forecast: $19.33
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +353.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.63
Current Ratio: 3.47
Quick Ratio: 3.45

Sales & Book Value

Annual Sales: $12.83 million
Price / Sales: 17.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.14 per share
Price / Book: 3.74

Miscellaneous

Outstanding Shares: 51,750,000
Free Float: 35,192,000
Market Cap: $220.46 million
Optionable: Not Optionable
Beta: 0.99

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Frederic Cren (Age 57)
Co-Founder, CEO & Chairman
Comp: $539.62k

Dr. Pierre Broqua Ph.D. (Age 61)
Co-Founder, Chief Scientific Officer, Deputy CEO & Director
Comp: $404.75k

Mr. Jean Volatier (Age 58)
Chief Financial Officer

Alice Roudot-Ketelers Pharm.D.
Chief Operating Officer

Mr. Eric Duranson L.L.M. (Age 49)
Gen. Counsel

Ms. Nathalie Harroy (Age 56)
Head of HR

Dr. Irena Konstantinova
Head of Biology & Pharmacology

Dr. Michael Cooreman (Age 65)
Chief Medical Officer

Mr. Jean-Paul Dutertre M.D.
Head of Pharmacovigilance

Key Competitors

View All Competitors

IVA Stock - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IVA shares.
View IVA analyst ratings or view top-rated stocks.
What is Inventiva's stock price forecast for 2023?: 5 brokerages have issued 12 month price objectives for Inventiva's stock. Their IVA share price forecasts range from $11.00 to $35.00. On average, they expect the company's share price to reach $19.33 in the next year. This suggests a possible upside of 353.8% from the stock's current price.
View analysts price targets for IVA or view top-rated stocks among Wall Street analysts.
How have IVA shares performed in 2023?: Inventiva's stock was trading at $4.46 at the beginning of the year. Since then, IVA stock has decreased by 4.5% and is now trading at $4.26.
View the best growth stocks for 2023 here.
Are investors shorting Inventiva?: Inventiva saw a decrease in short interest in September. As of September 15th, there was short interest totaling 90,900 shares, a decrease of 5.6% from the August 31st total of 96,300 shares. Based on an average trading volume of 25,200 shares, the days-to-cover ratio is currently 3.6 days.
View Inventiva's Short Interest.
When is Inventiva's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, September 28th 2023.
View our IVA earnings forecast.
When did Inventiva IPO?: (IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

What is Inventiva's stock symbol?: Inventiva trades on the NASDAQ under the ticker symbol "IVA."
How do I buy shares of Inventiva?: Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Inventiva's stock price today?: One share of IVA stock can currently be purchased for approximately $4.26.
How much money does Inventiva make?: Inventiva (NASDAQ:IVA) has a market capitalization of $220.46 million and generates $12.83 million in revenue each year.
How many employees does Inventiva have?: The company employs 109 workers across the globe.
How can I contact Inventiva?: Inventiva's mailing address is 50 RUE DE DIJON, DAIX I0, 21121. The official website for the company is www.inventivapharma.com. The company can be reached via phone at 33-3-80-44-75-00 or via email at finance@inventivapharma.com.

This page (NASDAQ:IVA) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Inventiva (IVA) Stock Forecast, Price & News

Inventiva MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Inventiva (NASDAQ:IVA) Stock

IVA Price History

IVA Stock News Headlines

IVA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

IVA Stock - Frequently Asked Questions

Overall MarketRank^™